LLY · 10-Q · 2026Q2 · Full report

Pricing and Reimbursement Pressure - GLP-1

ELI LILLY & Co · 2026-08-05 · Importance 38 · Surprise 24

U.S. price realization for Mounjaro and Zepbound declined despite strong volume growth, with Zepbound also affected by previously announced cash-pay price reductions. Outside the U.S., lower realized prices for Mounjaro were primarily driven by its addition to China’s National Reimbursement Drug List. Lilly noted that private payers and pharmacy benefit managers continue to negotiate access, manufacturer price concessions, rebates, and pharmacy reimbursement rates.

Key facts

• Lower realized prices in the U.S. for the three and six months ended June 30, 2026 were primarily driven by Zepbound and Mounjaro. source